Financial Architects, Inc Exelixis, Inc. Transaction History

Financial Architects, Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $5,868 - $7,672	-310 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$19.6 - $24.76 $6,076 - $7,675	310 New	310 $7,000
Q1 2019 May 03, 2019	SELL	$19.6 - $24.76 $6,076 - $7,675	-310 Closed	0 $0
Q4 2018 Feb 01, 2019	SELL	$13.65 - $21.8 $12,721 - $20,317	-932 Reduced 75.04%	310 $6,000
Q3 2018 Oct 29, 2018	SELL	$15.87 - $22.4 $18,552 - $26,185	-1,169 Reduced 48.49%	1,242 $22,000
Q2 2018 Aug 03, 2018	BUY	$18.56 - $22.45 $31,589 - $38,209	1,702 Added 240.06%	2,411 $52,000
Q1 2018 Apr 23, 2018	SELL	$22.15 - $31.89 $5,781 - $8,323	-261 Reduced 26.91%	709 $16,000
Q4 2017 Feb 12, 2018	SELL	$24.23 - $30.93 $5,645 - $7,206	-233 Reduced 19.37%	970 $29,000
Q3 2017 Nov 01, 2017	BUY	$23.35 - $29.24 $28,090 - $35,175	1,203	1,203 $30,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.